Interleukin-12 promotes recovery from viral encephalitis.
Infusion of interleukin-12 (IL-12) enhances recovery from lethal experimental vesicular stomatitis virus (VSV) infection of the central nervous system (CNS). Interleukin-12 treatment resulted in: 1) increased survival frequency; 2) faster recovery from weight loss; 3) substantially decreased VSV titers in brain homogenates and diminished immunohistochemical detection of VSV antigens in tissue sections; 4) earlier and increased CNS expression of types 1, 2, and 3 nitric oxide synthase (NOS) and both major histocompatibility complex (MHC) class I and class II antigens; 5) earlier and increased blood and CNS levels of tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). These results suggest that IL-12 enhances recovery from VSV infection of the CNS.
Komatsu
T
T
Department of Biology, New York University, New York, USA.
Barna
M
M
Reiss
C S
CS
D000818:Animals; D001921:Brain / Q000276:immunology / Q000821:virology; D016466:CHO Cells; D006224:Cricetinae; D004195:Disease Models, Animal; D018792:Encephalitis, Viral / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology; D018664:Interleukin-12 / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009017:Morbidity; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D011817:Rabbits; D018353:Rhabdoviridae Infections / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014721:Vesicular stomatitis Indiana virus / Q000276:immunology*; D015431:Weight Loss
D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D007371:Interferon-gamma; D019001:Nitric Oxide Synthase